Literature DB >> 6190242

A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers.

J Dawes, K J Clemetson, G O Gogstad, J McGregor, P Clezardin, C V Prowse, D S Pepper.   

Abstract

A radioimmunoassay was developed for the platelet alpha-granule protein thrombospondin; concentrations of thrombospondin as low as 3 ng ml-1 could be measured. There was no interference from other components of human biological fluids and no crossreactivity with beta-thromboglobulin (beta-TG) or platelet factor 4 (PF4). Plasma samples were stable when stored at -20 degrees C. Normal human plasma contained 105.0 +/- 31.0 ng thrombospondin ml-1 compared with beta-TG concentrations of 37.2 +/- 10.9 ng ml-1 and PF4 concentrations of 14.7 +/- 10.1 ng ml-1 when samples were carefully taken into a platelet inhibitor cocktail and processed at 0-4 degrees C. Release of thrombospondin during clotting of blood occurred at the same time as that of beta-TG and PF4 and resulted in a serum concentration of 17.5 +/- 5.5 micrograms ml-1. Assay of whole blood gave a platelet thrombospondin content of 89.1 +/- 28.3 ng/10(6) platelets. The concentration in normal urine fluctuated widely from 3 to 22.5 ng ml-1, and was unrelated to urine flow. The half-life of thrombospondin in vivo was about 9 h, much longer than that of either beta-TG or PF4. Unlike PF4, it was not released into the blood following an intravenous heparin injection. Bovine, ovine, canine and porcine sera contained thrombospondin which crossreacted immunologically with the human molecule; these species would be suitable animal models for the study of thrombospondin and its value as a platelet release marker.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190242     DOI: 10.1016/0049-3848(83)90212-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

Authors:  O V Volpert; J Lawler; N P Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

2.  Effects of age and platelet-rich plasma on ACL cell viability and collagen gene expression.

Authors:  Mingyu Cheng; Victor M Johnson; Martha M Murray
Journal:  J Orthop Res       Date:  2011-07-11       Impact factor: 3.494

3.  Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation.

Authors:  Pallavi Garg; Shiqi Yang; Anguo Liu; Manuel A Pallero; Donald J Buchsbaum; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-29       Impact factor: 5.464

Review 4.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 5.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

6.  Calumenin but not reticulocalbin forms a Ca2+-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis.

Authors:  Gry Aune Westergaard Hansen; Henrik Vorum; Christian Jacobsen; Bent Honoré
Journal:  Mol Cell Biochem       Date:  2008-08-08       Impact factor: 3.396

7.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

8.  The CD47-binding peptide of thrombospondin-1 induces defenestration of liver sinusoidal endothelial cells.

Authors:  Lakshmi Venkatraman; Lisa Tucker-Kellogg
Journal:  Liver Int       Date:  2013-06-26       Impact factor: 5.828

9.  TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.

Authors:  Jie Ren; Changwei Gu; Yong Yang; Jun Xue; Yuhao Sun; Fangfang Jian; Dongjiang Chen; Liuguan Bian; Qingfang Sun
Journal:  J Cell Mol Med       Date:  2019-04-23       Impact factor: 5.310

10.  TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.

Authors:  Wende Yang; Wei Li; Fan Pan; Xiao-Yan Yang; Xiaoxu Zhao; Li Qin; Yunlong Pan
Journal:  Oncol Lett       Date:  2020-01-21       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.